FDA Peptide Reclassification 2026: What Researchers Need to Know

The FDA's ongoing regulatory actions against compounding pharmacies have fundamentally reshaped the landscape of research peptides in the United States. What began as targeted enforcement in 2022 has expanded into a sweeping reclassification effort that by 2026 has removed dozens of peptides from legitimate compounding channels.

This article breaks down what happened, where things currently stand, and what it means for researchers, clinicians, and the broader peptide science community.

Background: How Peptides Were Compounded Legally

Before diving into the reclassification, it helps to understand the regulatory framework that allowed peptides to exist in a legal gray zone for years.

503A vs. 503B Compounding

Under the Federal Food, Drug, and Cosmetic Act, two types of pharmacy compounding are permitted:

• 503A pharmacies prepare customized medications for individual patients with a valid prescription. They must use FDA-approved bulk drug substances or substances on the FDA's approved bulk list.
• 503B outsourcing facilities produce larger batches of compounded drugs for healthcare settings without patient-specific prescriptions. They operate under stricter oversight, including cGMP (current Good Manufacturing Practice) standards.

For years, many peptides existed in a workable space: not FDA-approved as drugs, but tolerated for compounding under the premise that they were on the agency's "may be used" list or simply hadn't been addressed yet. The FDA's "bulk drug substances" evaluation process, known as the 503B Bulks List process, was the mechanism that would eventually be used to remove them.

The 2022–2024 Removal Wave

Category 1, 2, and Pending

The FDA evaluates bulk drug substances for compounding eligibility and places them into three categories:

• Category 1: Appropriate for use in compounding
• Category 2: Not appropriate for use in compounding
• Pending: Still under review

In 2022 and 2023, the FDA began issuing final decisions that moved several well-known research peptides to Category 2 — effectively banning their use in both 503A and 503B compounding.

Key Peptides Moved to Category 2

The following peptides were among those placed on the FDA's "do not compound" list during this period:

Ipamorelin, CJC-1295, and Sermorelin entered a more complex status: some remain in a pending or tolerated state depending on the compounding context, though enforcement pressure has increased significantly.

What Changed in 2025–2026

Increased Enforcement Actions

The FDA's Office of Criminal Investigations and state pharmacy boards escalated enforcement in 2025. Warning letters sent to compounding pharmacies producing Category 2 peptides became more frequent, and several prominent 503B facilities received FDA 483 observations specifically citing prohibited peptide production.

By early 2026, the practical effect is significant: most licensed compounding pharmacies have removed BPC-157 and TB-500 from their formularies entirely, or risk losing their compounding license.

The Semaglutide Exception

Semaglutide and tirzepatide — GLP-1 agonists technically categorized as peptides — followed a different trajectory. During the FDA-declared shortage of Ozempic and Wegovy, 503B facilities were permitted to compound semaglutide. As of mid-2026, the shortage status remains contested, with ongoing legal battles between compounding pharmacies and Novo Nordisk over whether the shortage declaration is still valid. This has no impact on the research peptide reclassifications.

Ongoing Legal Challenges

Several physician and compounding industry groups have filed legal challenges to the FDA's Category 2 determinations, arguing the agency:

1. Did not adequately account for the distinction between pharmaceutical-grade compounding and legitimate research use

2. Applied an inappropriately high evidentiary standard to research chemicals that were never intended to be FDA-approved drugs

3. Failed to consider the lack of viable commercial alternatives for conditions where compounded peptides were being prescribed off-label

As of April 2026, these challenges remain in various stages of federal district court proceedings. No injunctions have been granted to halt enforcement.

What This Means for the Research Community

Grey Market Shift

The removal of legitimate compounding channels has not eliminated demand — it has shifted supply. Research chemical vendors, operating under a "for research use only" framework and not subject to pharmacy compounding regulations, have become the primary source of peptides for individuals who were previously obtaining them from compounding pharmacies.

This creates a meaningful difference in product quality oversight. Compounding pharmacies, particularly 503B facilities, were required to test products for potency, sterility, and endotoxin levels. Research chemical vendors operate under no such regulatory framework, though reputable vendors provide third-party certificates of analysis.

Clinical Research Impact

For researchers conducting or designing studies involving peptides like BPC-157, the reclassification creates hurdles but not insurmountable ones. Academic and institutional researchers can still work with these compounds under IND (Investigational New Drug) applications or through IRB-approved animal research protocols. The peptides themselves are not illegal to possess or research — they simply cannot be compounded and dispensed as medications.

What Remains Available

Not all peptides are affected equally. As of 2026:

• Sermorelin: Remains available through 503A compounding with a prescription in many states, though 503B production is more restricted
• Ipamorelin / CJC-1295: Status varies by state and compounding type — some 503A pharmacies still dispense these
• NAD+: Available through compounding; IV NAD+ at clinics remains a growing market
• Thymosin Alpha-1: Available for compounding for certain immune-related applications
• Semaglutide / Tirzepatide: Contested shortage exemption — production has continued but faces legal uncertainty

The Research Perspective

It's important to note what the FDA's Category 2 designation does and does not say about a peptide's scientific merit.

The FDA's evaluation for compounding eligibility focuses on whether a substance is appropriate to dispense as a medication — not on whether the underlying research is valid or promising. BPC-157's Category 2 status does not mean the decades of preclinical research showing tissue healing properties are invalidated. It means the FDA determined the available data is insufficient to support dispensing it as a compounded drug.

The scientific community continues to produce research on these compounds. In 2025 alone, over 40 new peer-reviewed papers were published on BPC-157 across gastroenterology, orthopedics, and neurology journals. The regulatory and scientific tracks are largely parallel, not convergent.

Looking Ahead

The peptide regulatory landscape in 2026 remains in motion. Several developments to watch:

1. IND-enabled clinical trials: Advocacy groups are pushing for properly-funded Phase I safety trials for BPC-157 and TB-500, which would be the most effective path to eventual legitimate medical access

2. International frameworks: Research in Europe, Australia, and Asia operates under different regulatory environments. Trials conducted abroad may generate the human safety data that could eventually influence FDA reconsideration

3. Congress: Proposed legislation to create a clearer "research compound" category separate from the pharmaceutical drug pathway has been discussed but not yet moved forward

For researchers, the most important principle remains consistent: work within the applicable regulatory framework for your specific use case, ensure compounds are appropriately characterized, and maintain rigorous documentation of research purpose and protocols.

Note: This article is for educational and research context only. KnowYourPeptide does not facilitate the purchase of any compound. Always consult applicable regulations for your jurisdiction and work with qualified legal and medical advisors.